Clinical trials: Olanzapine
- Drug or intervention Olanzapine
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
- Trial name
- DayBreak (NCT02717195)
- Testing
- Risperidone, Olanzapine, Lu AF35700
- Where
- 147 sites in United States, Bulgaria and 12 more
- Volunteers
- 1,098 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder I or II
Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine
A non randomized study to validate the MATHYS Scale in a population of in and outpatients greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and treated with olanzapine.
- Trial name
- NCT00259272
- Testing
- olanzapine
- Where
- 16 sites in France
- Volunteers
- 141 people
- Sponsor
- Eli Lilly and Company
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC
Bipolar I Disorder, Schizophrenia
Study in Adolescents With Schizophrenia or Bipolar Disorder
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
- Trial name
- NCT00982020
- Testing
- Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
- Where
- 14 sites in United States, Poland and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Drug-induced Weight Gain
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
- Trial name
- NCT05857566
- Testing
- RDX-002 + Olanzipine, Olanzapine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Response Pharmaceuticals
Stable Schizophrenia
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to…
- Trial name
- NCT03319953
- Testing
- TAK-041, Second Generation Antipsychotics (SGA)
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
Phase IIA Study in Patients With Schizophrenia
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
- Trial name
- NCT00686998
- Testing
- AZD2624, Olanzapine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
The purpose of this trial is to assess the effect of asenapine 2.5 and 5 mg sublingually twice daily (BID) compared with placebo in the treatment of schizophrenia (overall symptoms) as measured by the Positive and Negative…
- Trial name
- NCT01617187
- Testing
- Asenapine, Olanzapine
- Volunteers
- 360 people
- Sponsor
- Organon and Co
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
The purpose of this study was to evaluate the efficacy of ASP4345 on cognitive impairment compared to placebo using change from baseline in MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score (excluding…
- Trial name
- NCT03557931
- Testing
- ASP4345, risperidone, quetiapine
- Where
- 27 sites in United States
- Volunteers
- 233 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Manic or Mixed Episode Associated With Bipolar I Disorder
Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder
The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC [Study BMAC]) will be examined.
- Trial name
- NCT00266630
- Testing
- olanzapine, lithium, valproate
- Where
- 11 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
The primary objective of this study is to evaluate the efficacy of TV-44749 in adult participants with schizophrenia. A key secondary objective is to further evaluate the efficacy of TV-44749 based on additional parameters in…
- Trial name
- SOLARIS (NCT05693935)
- Testing
- TV-44749
- Where
- 82 sites in United States, Bulgaria and 3 more
- Volunteers
- 675 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia
A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
A study to evaluate the safety and efficacy of treatment with MK-8998 as compared to placebo and olanzapine for acutely psychotic patients with schizophrenia.
- Trial name
- NCT00827918
- Testing
- MK-8998, Comparator: Olanzapine
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Schizoaffective Disorders
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
The goal of this study is to answer the following questions: Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine Whether taking amantadine…
- Trial name
- NCT00401973
- Testing
- olanzapine, amantadine, metformin
- Where
- 15 sites in United States, Brazil and 5 more
- Volunteers
- 199 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
This 3-part dose titration study will assess elpipodect safety, tolerability, pharmacokinetics (PK), and central nervous system activity.
- Trial name
- NCT02181803
- Testing
- Elpipodect, Base Monotherapy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC